{"schema_version":"1","generated_at":"2026-10-28T06:24:02.395Z","data_as_of":null,"url":"https://www.findmykol.com/kol/stephen-tyring","json_url":"https://www.findmykol.com/kol/stephen-tyring/profile.json","record_kind":"basic","profile_kind":"clinical","person":{"slug":"stephen-tyring","name":"Stephen Tyring","credential":"MD, PhD","title":"Clinical Professor, Departments of Dermatology, Microbiology/Molecular Genetics and Internal Medicine","specialty":"Dermatology","specialty_raw":"Dermatology","therapeutic_area":"Dermatology","therapeutic_areas":["Dermatology"],"institution":"Center for Clinical Studies","institution_url":"https://www.findmykol.com/institution/center-for-clinical-studies","city":"Webster","state":"TX","region":{"label":"South Central","url":"https://www.findmykol.com/region/south-central"},"country":{"name":"United States","code":"US","status":"verified"}},"identifiers":{"npi":"1245227263","orcid":"0000-0002-3337-0580","openalex":"A5000478173"},"summary":"Stephen Tyring is Clinical Professor, Departments of Dermatology, Microbiology/Molecular Genetics and Internal Medicine at Center for Clinical Studies. OpenAlex indexes 1,174 publications with 38,047 citations (h-index 74). By OpenAlex citation count, this profile ranks in the top 1% of Dermatology profiles in the FindMyKOL directory.","overview":{"text":"Stephen Tyring, MD PHD, is Clinical Professor, Departments of Dermatology, Microbiology/Molecular Genetics and Internal Medicine at University of Texas Health Science Center at Houston (McGovern Medical School). The public record shows 634 publications with 25,345 citations (h-index 74), centered on Dermatology and Skin Diseases, Herpesvirus Infections and Treatments, Psoriasis: Treatment and Pathogenesis. It also documents an investigator role on 6 registered clinical trials, industry payments reported by 50 companies, 3 NIH-funded awards (1989–2004).","bullets":["Most recent indexed publication: 2026 · Proceedings (Baylor University. Medical Center)","Top research focus: Dermatology and Skin Diseases","6 registered trials on ClinicalTrials.gov","Open Payments reporting from 50 companies"],"generated_at":"2026-10-27"},"focus":{"indications":[{"label":"Herpes Zoster","therapeutic_area":"Infectious Disease","trials":3,"topics":0,"strength":9},{"label":"Psoriasis / Psoriatic Arthritis","therapeutic_area":"Rheumatology/Immunology","trials":1,"topics":1,"strength":4},{"label":"Immunologic Deficiency Syndromes","therapeutic_area":"Rheumatology/Immunology","trials":1,"topics":0,"strength":3},{"label":"Neuralgia","therapeutic_area":"Neurology","trials":1,"topics":0,"strength":3},{"label":"Onychomycosis","therapeutic_area":"Dermatology","trials":1,"topics":0,"strength":3},{"label":"Molluscum Contagiosum","therapeutic_area":"Dermatology","trials":1,"topics":0,"strength":3},{"label":"Atopic Dermatitis / Eczema","therapeutic_area":"Dermatology","trials":0,"topics":1,"strength":1},{"label":"Psoriasis (Derm)","therapeutic_area":"Dermatology","trials":0,"topics":1,"strength":1}],"research_topics":["Dermatology and Skin Diseases","Herpesvirus Infections and Treatments","Psoriasis: Treatment and Pathogenesis","Cervical Cancer and HPV Research","Cytomegalovirus and herpesvirus research"],"drugs_studied":{"total":12,"shown":3,"withheld":9,"rows":[{"name":"Skyrizi","generic":"Risankizumab","trials":0,"payments":142,"publications":2,"mentions":144},{"name":"Cosentyx","generic":"Secukinumab","trials":0,"payments":83,"publications":2,"mentions":85},{"name":"Ilumya","generic":"Tildrakizumab","trials":0,"payments":36,"publications":1,"mentions":37}]},"works_with":{"total":30,"shown":3,"withheld":27,"rows":[{"name":"Abbvie Inc.","trials":0,"payments":335,"mentions":335},{"name":"Janssen Biotech, Inc.","trials":0,"payments":186,"mentions":186},{"name":"Pfizer Inc.","trials":0,"payments":144,"mentions":144}]}},"scholarship":{"works_count":1174,"cited_by_count":38047,"h_index":74,"i10_index":299,"latest_activity_year":2026,"citation_standing":{"top_percent":1,"cohort":"Dermatology","method":"https://www.findmykol.com/about#citation-standing"},"source":"works"},"payments":{"company_count":50,"program_years":{"first":2021,"last":null},"rows_total":124,"shown":3,"withheld":121,"rows":[{"payer":"ABBVIE INC.","program_year":2025,"amount_usd":35676.58,"payment_count":50,"source_url":"https://openpaymentsdata.cms.gov/search?query=1245227263"},{"payer":"Janssen Biotech, Inc.","program_year":2025,"amount_usd":19622.99,"payment_count":42,"source_url":"https://openpaymentsdata.cms.gov/search?query=1245227263"},{"payer":"Galderma Laboratories, L.P.","program_year":2025,"amount_usd":14841.22,"payment_count":28,"source_url":"https://openpaymentsdata.cms.gov/search?query=1245227263"}],"record_url":"https://openpaymentsdata.cms.gov/search?query=1245227263","source":"payments"},"prescribing":{"data_year":2024,"areas_total":7,"areas_shown":3,"areas":[{"area":"Dermatology","share_pct":27.4,"classes_total":5,"classes":[{"class":"Corticosteroid","setting":"mixed","share_pct":20.6,"drugs":[{"name":"Triamcinolone Acetonide","share_pct":81},{"name":"Halobetasol Propionate","share_pct":9},{"name":"Triamcinolone acetonide","share_pct":6.9},{"name":"Methylprednisolone","share_pct":3.1}],"max_beneficiaries":null},{"class":"Interleukin-4 Receptor alpha Antagonist","setting":"prescribed","share_pct":3,"drugs":[{"name":"Dupixent Pen","share_pct":100}],"max_beneficiaries":16}]},{"area":"Anti-infectives","share_pct":26.8,"classes_total":5,"classes":[{"class":"Azole Antifungal","setting":"prescribed","share_pct":13.7,"drugs":[{"name":"Ketoconazole","share_pct":100}],"max_beneficiaries":136},{"class":"Tetracycline-class Drug","setting":"prescribed","share_pct":6.6,"drugs":[{"name":"Doxycycline Hyclate","share_pct":100}],"max_beneficiaries":59}]},{"area":"Sensory organs","share_pct":15.9,"classes_total":1,"classes":[{"class":"Corticosteroid","setting":"prescribed","share_pct":15.9,"drugs":[{"name":"Clobetasol Propionate","share_pct":69.8},{"name":"Desonide","share_pct":16.4},{"name":"Hydrocortisone","share_pct":7.4},{"name":"Betamethasone Dipropionate","share_pct":6.5}],"max_beneficiaries":null}]}],"care_setting":{"dominant":"office","data_year":2024,"office_pct":100,"facility_pct":0},"source":"medicare"},"funding":{"award_count":3,"fiscal_years":{"first":1989,"last":2004},"rows_total":92,"shown":3,"withheld":89,"rows":[{"project":"R03CA030730","title":"Genetic Resistance to Oncogenic Human Papillomaviruses","fiscal_year":2004,"amount_usd":69910,"organization":"UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON","source_url":"https://reporter.nih.gov/quickSearch/R03CA030730"},{"project":"R03CA030730","title":"Genetic Resistance to Oncogenic Human Papillomaviruses","fiscal_year":2003,"amount_usd":71062,"organization":"UNIVERSITY OF TEXAS MEDICAL BR GALVESTON","source_url":"https://reporter.nih.gov/quickSearch/R03CA030730"},{"project":"M01RR000073","title":"ABT 606 VS ACYCLOVIR FOR TREATMENT OF HERPES ZOSTER","fiscal_year":2002,"amount_usd":279290,"organization":"UNIVERSITY OF TEXAS MEDICAL BR GALVESTON","source_url":"https://reporter.nih.gov/quickSearch/M01RR000073"}],"source":"grants"},"publications":{"total":5,"shown":5,"withheld":4,"matched_by":"ORCID record, linked to PubMed","recent":[{"title":"Clinical progression of a smallpox postvaccination response.","year":2026,"journal":"Proceedings (Baylor University. Medical Center)","types":["Journal Article","Case Reports"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/42478786/","status":"verified"},{"title":"Switching to ustekinumab biosimilars for plaque psoriasis: A systematic review and meta-analysis.","year":2026,"journal":"Journal of the European Academy of Dermatology and Venereology : JEADV","types":["Letter"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/42447177/","status":"verified"},{"title":"A likely case of guttate psoriasis precipitated by syphilis: a novel association.","year":2026,"journal":"Proceedings (Baylor University. Medical Center)","types":["Journal Article"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/42417477/","status":"verified"},{"title":"A novel oral interleukin-23 receptor antagonist peptide, icotrokinra, for moderate-to- severe plaque psoriasis: a systematic review and meta-analysis of randomized controlled trials.","year":2026,"journal":"Inflammopharmacology","types":["Journal Article","Meta-Analysis","Systematic Review"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/41774413/","status":"verified"},{"title":"Buffalopox: An emerging cutaneous disease in humans.","year":2025,"journal":"Journal of the European Academy of Dermatology and Venereology : JEADV","types":["Case Reports","Journal Article"],"source_url":"https://pubmed.ncbi.nlm.nih.gov/38126940/","status":"verified"}],"most_cited":{"total":1174,"shown":5,"withheld":1169,"rows":[{"title":"Secukinumab in Plaque Psoriasis — Results of Two Phase 3 Trials","year":2014,"cited_by_count":1993,"type":"article","source_url":"https://doi.org/10.1056/nejmoa1314258"},{"title":"Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial","year":2005,"cited_by_count":1069,"type":"article","source_url":"https://doi.org/10.1016/s0140-6736(05)67763-x"},{"title":"Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial","year":2007,"cited_by_count":887,"type":"article","source_url":"https://doi.org/10.1016/j.jaad.2007.09.010"},{"title":"Recommendations for the Management of Herpes Zoster","year":2006,"cited_by_count":866,"type":"article","source_url":"https://doi.org/10.1086/510206"},{"title":"Phase 3 Studies Comparing Brodalumab with Ustekinumab in Psoriasis","year":2015,"cited_by_count":828,"type":"article","source_url":"https://doi.org/10.1056/nejmoa1503824"}]},"source":"publications"},"network":{"coauthors_total":40,"shown":3,"withheld":37,"coauthors":[{"name":"Peter L. Rady","coauthored_works":94},{"name":"Natalia Mendoza","coauthored_works":47,"profile_url":"https://www.findmykol.com/kol/natalia-mendoza"},{"name":"Reuben K. Matalon","coauthored_works":39}],"source":"works"},"recognition":{"education":{"total":5,"shown":5,"rows":[{"value":"MD (heading: \"MD, PhD, MBA\"; medical school listed as The University of Texas Medical Branch, Galveston, Texas). Corroborates NPPES credential MD PHD in part.","source_url":"https://med.uth.edu/dermatology/faculty/stephen-k-tyring-m-d-ph-d-m-b-a","status":"verified","collected_at":"2026-10-27"},{"value":"PhD, Medical Microbiology, Texas Tech University","source_url":"https://med.uth.edu/dermatology/faculty/stephen-k-tyring-m-d-ph-d-m-b-a","status":"verified","collected_at":"2026-10-27"},{"value":"MBA, Rice University","source_url":"https://med.uth.edu/dermatology/faculty/stephen-k-tyring-m-d-ph-d-m-b-a","status":"verified","collected_at":"2026-10-27"},{"value":"Board certified, Dermatology","source_url":"https://med.uth.edu/dermatology/faculty/stephen-k-tyring-m-d-ph-d-m-b-a","status":"verified","collected_at":"2026-10-27"},{"value":"Board certified, Internal Medicine","source_url":"https://med.uth.edu/dermatology/faculty/stephen-k-tyring-m-d-ph-d-m-b-a","status":"verified","collected_at":"2026-10-27"}]},"roles":{"total":1,"shown":1,"rows":[{"value":"President, Texas Dermatological Society (2009-2010)","source_url":"https://practiceupdate.com/explore/user/1069/1","status":"provisional","collected_at":"2026-10-27"}]},"secondary_affiliations":{"total":2,"shown":2,"rows":[{"value":"Center for Clinical Studies (medical director)","source_url":"https://www.hmpgloballearningnetwork.com/site/thederm/spotlight/conversation-stephen-k-tyring-md-phd-mba","status":"provisional","collected_at":"2026-10-27"},{"value":"Dermatological Associates of Texas (Houston Skin)","source_url":"https://www.hmpgloballearningnetwork.com/site/thederm/spotlight/conversation-stephen-k-tyring-md-phd-mba","status":"provisional","collected_at":"2026-10-27"}]},"media":{"total":2,"shown":2,"rows":[{"value":"Spotlight Q&A, HMP Global Learning Network (January 2026)","source_url":"https://www.hmpgloballearningnetwork.com/site/thederm/spotlight/conversation-stephen-k-tyring-md-phd-mba","status":"provisional","collected_at":"2026-10-27"},{"value":"Dermcast.live podcast episode on off-label use of medications","source_url":"https://dermcast.live/stephen-tyring-md-discusses-off-label-use-of-medications/amp/","status":"provisional","collected_at":"2026-10-27"}]}},"contact":{"address_1":"451 N TEXAS AVE","city":"Webster","state":"TX","zip":"77598-4927","phone":"281-333-2288","source_url":"https://npiregistry.cms.hhs.gov/provider-view/1245227263","source":"identity"},"similar":[{"name":"Robert Modlin","slug":"robert-modlin","institution":"University of California, Los Angeles","specialty":"Dermatology","url":"https://www.findmykol.com/kol/robert-modlin","json_url":"https://www.findmykol.com/kol/robert-modlin/profile.json"},{"name":"Heidi Kong","slug":"heidi-kong","institution":"National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)","specialty":"Dermatology","url":"https://www.findmykol.com/kol/heidi-kong","json_url":"https://www.findmykol.com/kol/heidi-kong/profile.json"},{"name":"Jon Hanifin","slug":"jon-hanifin","institution":"Oregon Health & Science University (OHSU)","specialty":"Dermatology","url":"https://www.findmykol.com/kol/jon-hanifin","json_url":"https://www.findmykol.com/kol/jon-hanifin/profile.json"},{"name":"Victoria Werth","slug":"victoria-werth","institution":"Perelman School of Medicine at the University of Pennsylvania","specialty":"Dermatology","url":"https://www.findmykol.com/kol/victoria-werth","json_url":"https://www.findmykol.com/kol/victoria-werth/profile.json"}],"coverage":{"note":"A basic record from the physician directory. Sections absent here were not yet checked for this person, so absence means not yet looked, never none found.","not_yet_checked":["congress","network","presence","recognition"]},"not_included":{"note":"This document is the public layer: neutral facts cited to their source. Judgments (influence tier, archetype, trajectory commentary) and the itemized rows past each section's public teaser are account features and are not served here or to crawlers.","withheld_rows":{"payments":121,"funding":89,"publications":4,"network":37}},"sources":{"orcid":{"name":"ORCID","url":"https://orcid.org","provides":"The verified researcher identity that anchors authorship"},"identity":{"name":"NPPES (CMS)","url":"https://npiregistry.cms.hhs.gov","provides":"Identity, specialty and practice location for every U.S. clinician","coverage":"Practice location (not mailing) from the NPPES record","record_last_updated":"2008-11-14","collected_at":"2026-07-28"},"works":{"name":"OpenAlex","url":"https://openalex.org","provides":"Citations, h-index, research topics, most-cited works and congress abstracts","collected_at":"2026-10-27"},"payments":{"name":"CMS Open Payments","url":"https://openpaymentsdata.cms.gov","provides":"Industry payments reported to CMS, by company and program year","disclaimer":"Payments are publicly reported to CMS. Their existence does not imply wrongdoing; CMS does not interpret these data.","coverage":"Program years 2021 onward","collected_at":"2026-10-27"},"medicare":{"name":"CMS Medicare Part D Prescribers and Part B","url":"https://data.cms.gov/provider-summary-by-type-of-service","provides":"Share of this prescriber's Medicare fee-for-service prescribing by drug class and therapeutic area, classified with WHO ATC and NLM RxClass","disclaimer":"Proportions of the prescriber's own classified prescribing, never patient counts or dollar amounts. Fee-for-service only; CMS publishes about 17 months after the fact and suppresses counts of ten patients or fewer.","data_year":2024},"grants":{"name":"NIH RePORTER","url":"https://reporter.nih.gov","provides":"Federally funded research awards, by fiscal year","collected_at":"2026-10-27"},"publications":{"name":"PubMed (NLM)","url":"https://pubmed.ncbi.nlm.nih.gov","provides":"Peer-reviewed publications, linked to the PubMed record","collected_at":"2026-10-27"}},"methodology_url":"https://www.findmykol.com/about#methodology"}